Loading…
Quarterly Financial Report Reauthorization Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
81pct
94d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.) Quarterly Financial Report Reauthorization Act (Sec. 2) Extends the authority of the Department of Commerce to conduct the quarterly financial report program through September 30, 2030, under which Commerce collects and publishes quarterly financial statistics of business operations, organization, practices, management, and relation to other businesses, including data on sales, expenses, assets, liabilities, and other measures of financial condition.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (7)
2016 · fourth_quarter · Health Issues
Became Public Law No: 114-72.
Became Public Law No: 114-72.
Signed by President.
Signed by President.
Presented to President.
Presented to President.
Motion to reconsider laid on the table Agreed to without objection.
On motion that the House agree to the Senate amendment Agreed to without objection. (text as House agreed to Senate amendment: CR H7060-7061)
Resolving differences -- House actions: On motion that the House agree to the Senate amendment Agreed to without objection.(text as House agreed to Senate amendment: CR H7060-7061)
Mr. Chaffetz asked unanimous consent that the House agree to the Senate amendment. (consideration: CR H7060-7061)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: Not reported · Firm income: $12,120
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: Not reported · Firm income: $12,120
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Client expense: $360,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · second_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: Not reported · Firm income: $8,160
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: Not reported · Firm income: $8,160
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Client expense: $630,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · first_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: Not reported · Firm income: $16,240
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: Not reported · Firm income: $16,240
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Client expense: $370,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · fourth_quarter · Government Issues
lobbied against inclusion of Poe ACS amendment on HR 2578 in FY 2016 omnibus appropriations bill (H.R. 2029); opposed HR 2255; discussed research implications of FCC ruling on Telephone Consumer Protection Act with federal agencies; expressed support for passage of H.R. 3116 (Quarterly Financial Reauthorization Act)
Client expense: Not reported · Firm income: Not reported
Government targets: Bureau of the Census, HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2015 · fourth_quarter · Economics/Economic Development
HR 3116, Quarterly Financial Report Reauthorization Act, All provisions.
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Aviation/Airlines/Airports
H.R. 4745 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act of 2015, H.R. 4660 Commerce, Justice, Science and Related Agencies Appropriations Act of 2015, H.R. 4156 Transparent Airfares Act, S. 223 FAA Air Transportation Modernization and Safety Improvement Act - All Provisions. H.R. 658 FAA Reauthorization and Reform Act of 2011- All provisions. S. 1546 and H.R.3116 Department of Homeland Security Reauthorization Act. H.R.4350. HR 1051 - To direct the Secretary of Homeland Security to designate John Wayne Airport in Orange County, California, as a U.S. Customs and Border Protection (CBP) port of entry, and for other purposes. H.R. 798 Responsible Skies Act of 2015. S. 1068 Consumer Drone Safety Act. SWAPA National Airline Policy.
Client expense: $40,000 · Firm income: Not reported
Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT)
2015 · fourth_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Client expense: $600,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · third_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: Not reported · Firm income: $42,400
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: Not reported · Firm income: $42,400
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Client expense: $410,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Aviation/Airlines/Airports
H.R. 4745 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act of 2015, H.R. 4660 Commerce, Justice, Science and Related Agencies Appropriations Act of 2015, H.R. 4156 Transparent Airfares Act, S. 223 FAA Air Transportation Modernization and Safety Improvement Act - All Provisions. H.R. 658 FAA Reauthorization and Reform Act of 2011- All provisions. S. 1546 and H.R.3116 Department of Homeland Security Reauthorization Act. H.R.4350. HR 1051 - To direct the Secretary of Homeland Security to designate John Wayne Airport in Orange County, California, as a U.S. Customs and Border Protection (CBP) port of entry, and for other purposes. H.R. 798 Responsible Skies Act of 2015. S. 1068 Consumer Drone Safety Act. SWAPA National Airline Policy.
Client expense: $40,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT)
2015 · second_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: Not reported · Firm income: $87,960
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: Not reported · Firm income: $87,960
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Client expense: $790,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Client expense: Not reported · Firm income: $30,000
2015 · first_quarter · Aviation/Airlines/Airports
H.R. 4745 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act of 2015, H.R. 4660 Commerce, Justice, Science, and Related Agencies Appropriations Act of 2015, H.R. 4156 Transparent Airfares Act, S.223 FAA Air Transportation Modernization and Safety Improvement Act - All provisions. H.R.658 FAA Reauthorization and Reform Act of 2011- All provisions. S.1546 and H.R.3116 Department of Homeland Security Reauthorization Act. H.R. 4350 and SWAPA National Airline Policy.
Client expense: $40,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT)
2015 · first_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: Not reported · Firm income: $61,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), and The Innovation Act (H.R. 9, 114th Cong.).
Client expense: Not reported · Firm income: $61,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: Not reported · Firm income: Not reported
2015 · first_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: Not reported
2015 · first_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: Not reported
Message on Senate action sent to the House.
Passed Senate with an amendment by Unanimous Consent.
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Measure laid before Senate by unanimous consent. (consideration: CR S7171)
Senate Committee on Homeland Security and Governmental Affairs discharged by Unanimous Consent.
Senate Committee on Homeland Security and Governmental Affairs discharged by Unanimous Consent.
Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H6198)
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H6198)
DEBATE - The House proceeded with forty minutes of debate on H.R. 3116.
Considered under suspension of the rules. (consideration: CR H6198-6199)
Mr. Chaffetz moved to suspend the rules and pass the bill.
Placed on the Union Calendar, Calendar No. 179.
Reported by the Committee on Oversight and Government Reform. H. Rept. 114-237.
Congress.gov source codes: 5000, H12200
Ordered to be Reported by Voice Vote.
Committee Consideration and Mark-up Session Held.
Committee Consideration and Mark-up Session Held.
Referred to the House Committee on Oversight and Government Reform.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| House |
| Markup by |
| July 23, 2015 |
| Oversight and Accountability Committee | House | Referred to | July 20, 2015 |
| September 24, 2015 |
| Reported in House | July 29, 2015 |
| Introduced in House | July 20, 2015 |
| Enrolled Bill | -- |
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE